%0 Journal Article
%T Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
%A Akiko Matsumoto
%A Ge Guo
%A Haruki Horiguchi
%A Hiroshi Itoh
%A Jiabin Zhao
%A Jun Morinaga
%A Keishi Miyata
%A Motoyoshi Endo
%A Shunshun Zhu
%A Taichi Sugizaki
%A Tsuyoshi Kadomatsu
%A Yuichi Oike
%A Zhe Tian
%J Archive of "NPJ Aging and Mechanisms of Disease".
%D 2017
%R 10.1038/s41514-017-0012-0
%X TA-1887-treated or insulin-treated severely diabetic mice show enhanced survival and increased body weight but does not alter food intake or energy expenditure. a left: Changes in body weight in db/db mice fed a high-fat diet (HF) or comparable mice treated with saline (HF£¿+£¿saline) or with TA-1887(HF£¿+£¿TA) or insulin (HF£¿+£¿Ins) (n£¿=£¿20¨C30). right: AUC for body weight at indicated periods. b Food intake of each group at 13, 37, and 72 days (n£¿=£¿6). c Proportion of animals surviving 4 months (n£¿=£¿20¨C30). d Representative appearance of mice in indicated groups at day 80. e Energy expenditure (EE) after 9 weeks of each treatment, as determined by indirect calorimetry (n£¿=£¿6). f Volume of lean body mass, total fat, visceral fat (v fat) and subcutaneous fat (s fat), as measured by computed tomography (CT) after 3 months of each treatment (n£¿=£¿6). Values shown are means£¿¡À£¿SEM. *p£¿<£¿0.05, **p£¿<£¿0.01 versus HF, and # p£¿<£¿0.05, ## p£¿<£¿0.01 versus HF£¿+£¿saline, and £¿£¿ p£¿<£¿0.01 versus HF£¿+£¿TA and £¿£¿ p£¿<£¿0.01 versus HF£¿+£¿In
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591191/